Drugs / Hu8F4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02530034 | Jan 2019 → Jan 2027 expected | acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts-1 +2 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hu8F4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530034 ↗ |
| Known as | Anti-pr1/hla-a2 monoclonal antibody hu8f4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594523 ↗ |
| Modality | Monoclonal antibody | “anti-PR1/HLA-A2 monoclonal antibody Hu8F4” NCT02530034 ↗ |
| Route | Intravenous | “administered intravenously” NCT02530034 ↗ |